BMRN
BioMarin Pharmaceutical Inc.
Price Chart
Latest Quote
$55.05
+0.03 (+0.05%)
Current Price
| Previous Close | $55.02 |
| Open | $55.04 |
| Day High | $55.62 |
| Day Low | $54.73 |
| Volume | 700,657 |
Stock Information
| Shares Outstanding | 193.28M |
| Total Debt | $1.44B |
| Cash Equivalents | $2.22B |
| Revenue | $3.24B |
| Net Income | $268.74M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.64B |
| P/E Ratio | 39.60 |
| EPS (TTM) | $1.39 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.87B |
| Sales | $3.24B |
| Income | $268.74M |
| Book/sh | $32.14 |
| Cash/sh | $11.50 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 3.94 |
| Current Ratio | 5.81 |
| Debt/Eq | 23.17 |
| EPS Growth TTM | -43.20% |
Returns & Margins
| ROA | 4.49% |
| ROE | 4.48% |
| Gross Margin | 51.16% |
| Operating Margin | 18.00% |
| Profit Margin | 8.29% |
Ownership
| Insider Ownership | 0.35% |
| Institutional Ownership | 102.68% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 8.52 |
| PEG | 0.68 |
| P/S | 3.28 |
| P/B | 1.71 |
Analyst Data
| Recommendation | buy |
| Target Price | $87.85 |
Technical Indicators
| SMA20 | $55.13 |
| SMA50 | $54.26 |
| SMA200 | $55.67 |
| RSI | 41.21 |
| ATR | 1.5821 |
| Shares Float | 192.09M |
| Short Float | 6.02% |
| Short Ratio | 4.79 |
| Volatility | 0.24 |
| Rel Volume | 0.31 |
Performance History
| Week | -0.88% |
| Month | +10.52% |
| Quarter | +0.04% |
| 6 Months | +6.34% |
| YTD | -7.40% |
| Year | +0.09% |
| 3 Years | -41.90% |
| 5 Years | -32.92% |
| 10 Years | -34.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $55.05 | 700,657 |
| 2026-06-17 | $55.02 | 1,708,300 |
| 2026-06-16 | $55.12 | 1,524,400 |
| 2026-06-15 | $55.65 | 1,458,300 |
| 2026-06-12 | $55.95 | 1,081,000 |
| 2026-06-11 | $55.54 | 1,603,900 |
| 2026-06-10 | $56.17 | 2,055,900 |
| 2026-06-09 | $57.91 | 2,767,300 |
| 2026-06-08 | $56.55 | 2,062,800 |
| 2026-06-05 | $56.77 | 2,232,700 |
| 2026-06-04 | $56.47 | 2,077,400 |
| 2026-06-03 | $54.66 | 2,268,000 |
| 2026-06-02 | $53.32 | 2,708,100 |
| 2026-06-01 | $55.03 | 2,818,100 |
| 2026-05-29 | $57.29 | 5,465,900 |
| 2026-05-28 | $52.74 | 1,808,900 |
| 2026-05-27 | $52.38 | 2,345,000 |
| 2026-05-26 | $52.88 | 1,803,800 |
| 2026-05-22 | $54.09 | 2,438,300 |
| 2026-05-21 | $54.10 | 4,571,500 |
| 2026-05-20 | $50.20 | 2,189,700 |
| 2026-05-19 | $49.81 | 2,598,700 |
| 2026-05-18 | $49.67 | 3,485,600 |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
đ° Latest News
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
StockStory âĸ 2026-06-11T09:05:37Z
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
Insider Monkey âĸ 2026-06-08T10:47:43Z
BioMarinâs VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story
Simply Wall St. âĸ 2026-06-05T06:08:07Z
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-03T15:30:05Z
Centene, Deckers and 14 Other âDividend Hopefulsâ
Barrons.com âĸ 2026-06-02T05:30:00Z
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
Motley Fool âĸ 2026-05-30T17:56:01Z
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development
Insider Monkey âĸ 2026-05-30T16:43:06Z
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com âĸ 2026-05-28T20:27:17ZWhy BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
StockStory âĸ 2026-05-23T05:00:55Z
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
StockStory âĸ 2026-05-22T18:44:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $657,271,000 | $527,066,000 | $489,887,000 | $463,854,000 |
| Cost Of Revenue | $717,442,000 | $580,235,000 | $532,062,000 | $503,023,000 |
| Total Revenue | $3,221,253,000 | $2,853,915,000 | $2,419,226,000 | $2,096,039,000 |
| Operating Revenue | $3,221,253,000 | $2,853,915,000 | $2,419,226,000 | $2,096,039,000 |
| Expenses | ||||
| Interest Expense | $10,899,000 | $12,666,000 | $17,335,000 | $13,814,000 |
| Total Expenses | $2,811,758,000 | $2,379,676,000 | $2,233,446,000 | $2,038,629,000 |
| Other Income Expense | $8,997,000 | $5,332,000 | $-38,215,000 | $90,138,000 |
| Other Non Operating Income Expenses | $8,997,000 | $-4,668,000 | $-38,215,000 | $-13,462,000 |
| Net Non Operating Interest Income Expense | $64,005,000 | $62,217,000 | $41,004,000 | $3,627,000 |
| Interest Expense Non Operating | $10,899,000 | $12,666,000 | $17,335,000 | $13,814,000 |
| Operating Expense | $2,094,316,000 | $1,799,441,000 | $1,701,384,000 | $1,535,606,000 |
| Selling And Marketing Expense | $530,200,000 | $476,700,000 | $488,400,000 | $450,300,000 |
| General And Administrative Expense | $622,800,000 | $532,300,000 | $404,000,000 | $372,900,000 |
| Total Other Finance Cost | - | $391,000 | $594,000 | $593,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Net Interest Income | $64,005,000 | $62,217,000 | $41,004,000 | $3,627,000 |
| Interest Income | $74,904,000 | $74,883,000 | $58,339,000 | $18,034,000 |
| Normalized Income | $348,901,000 | $418,979,927 | $167,645,000 | $43,512,385 |
| Net Income From Continuing And Discontinued Operation | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Total Operating Income As Reported | $409,478,000 | $484,214,000 | $185,774,000 | $160,974,000 |
| Average Dilution Earnings | $7,334,000 | $7,327,000 | $0 | $0 |
| Net Income Common Stockholders | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Net Income | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Net Income Including Noncontrolling Interests | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Net Income Continuous Operations | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Pretax Income | $482,480,000 | $541,763,000 | $188,563,000 | $149,576,000 |
| Special Income Charges | $0 | $10,000,000 | $0 | $103,600,000 |
| Interest Income Non Operating | $74,904,000 | $74,883,000 | $58,339,000 | $18,034,000 |
| Operating Income | $409,495,000 | $474,239,000 | $185,780,000 | $57,410,000 |
| Depreciation Amortization Depletion Income Statement | $19,386,000 | $43,257,000 | $62,211,000 | $62,800,000 |
| Depreciation And Amortization In Income Statement | $19,386,000 | $43,257,000 | $62,211,000 | $62,800,000 |
| Amortization Of Intangibles Income Statement | $19,386,000 | $43,257,000 | $62,211,000 | $62,800,000 |
| Gross Profit | $2,503,811,000 | $2,273,680,000 | $1,887,164,000 | $1,593,016,000 |
| Per Share | ||||
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 |
| Basic EPS | $1.82 | $2.25 | $0.89 | $0.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $2,120,927 | $0 | $5,551,385 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $572,936,000 | $640,855,000 | $310,284,000 | $161,759,000 |
| Total Unusual Items | $0 | $10,000,000 | $0 | $103,600,000 |
| Total Unusual Items Excluding Goodwill | $0 | $10,000,000 | $0 | $103,600,000 |
| Reconciled Depreciation | $79,557,000 | $96,426,000 | $104,386,000 | $101,969,000 |
| EBITDA (Bullshit earnings) | $572,936,000 | $650,855,000 | $310,284,000 | $265,359,000 |
| EBIT | $493,379,000 | $554,429,000 | $205,898,000 | $163,390,000 |
| Diluted Average Shares | $197,394,000 | $196,708,000 | $191,595,000 | $188,963,000 |
| Basic Average Shares | $191,787,000 | $190,027,000 | $187,834,000 | $185,266,000 |
| Diluted NI Availto Com Stockholders | $356,235,000 | $434,186,000 | $167,645,000 | $141,561,000 |
| Tax Provision | $133,579,000 | $114,904,000 | $20,918,000 | $8,015,000 |
| Gain On Sale Of Ppe | $0 | $10,000,000 | $0 | $108,000,000 |
| Amortization | $19,386,000 | $43,257,000 | $62,211,000 | $62,800,000 |
| Research And Development | $921,930,000 | $747,184,000 | $746,773,000 | $649,606,000 |
| Selling General And Administration | $1,153,000,000 | $1,009,000,000 | $892,400,000 | $823,200,000 |
| Other Gand A | $622,800,000 | $532,300,000 | $404,000,000 | $372,900,000 |
| Restructuring And Mergern Acquisition | - | $0 | $0 | $4,400,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,676,963,000 | $5,206,513,000 | $4,460,649,000 | $4,068,388,000 |
| Total Assets | $7,594,022,000 | $6,988,940,000 | $6,841,603,000 | $6,375,074,000 |
| Total Non Current Assets | $3,640,532,000 | $3,756,513,000 | $3,885,515,000 | $3,623,617,000 |
| Other Non Current Assets | $277,049,000 | $251,391,000 | $171,538,000 | $176,236,000 |
| Non Current Deferred Assets | $1,508,697,000 | $1,489,366,000 | $1,545,809,000 | $1,505,412,000 |
| Non Current Deferred Taxes Assets | $1,508,697,000 | $1,489,366,000 | $1,545,809,000 | $1,505,412,000 |
| Investmentin Financial Assets | $492,242,000 | $521,238,000 | $611,135,000 | $333,835,000 |
| Goodwill And Other Intangible Assets | $410,036,000 | $451,477,000 | $490,900,000 | $534,768,000 |
| Other Intangible Assets | $213,837,000 | $255,278,000 | $294,701,000 | $338,569,000 |
| Current Assets | $3,953,490,000 | $3,232,427,000 | $2,956,088,000 | $2,751,457,000 |
| Other Current Assets | $185,784,000 | $201,533,000 | $141,391,000 | $104,521,000 |
| Inventory | $1,298,883,000 | $1,232,653,000 | $1,107,183,000 | $894,083,000 |
| Receivables | $908,214,000 | $660,535,000 | $633,704,000 | $461,316,000 |
| Accounts Receivable | $908,214,000 | $660,535,000 | $633,704,000 | $461,316,000 |
| Cash Cash Equivalents And Short Term Investments | $1,560,609,000 | $1,137,706,000 | $1,073,810,000 | $1,291,537,000 |
| Cash And Cash Equivalents | $1,311,679,000 | $942,842,000 | $755,127,000 | $724,531,000 |
| Cash Equivalents | $895,919,000 | $613,223,000 | $525,451,000 | $261,283,000 |
| Cash Financial | $415,760,000 | $329,619,000 | $229,676,000 | $463,248,000 |
| Debt | ||||
| Total Debt | $605,861,000 | $602,712,000 | $1,095,751,000 | $1,093,394,000 |
| Long Term Debt And Capital Lease Obligation | $597,176,000 | $595,138,000 | $593,095,000 | $1,083,019,000 |
| Long Term Debt | $597,176,000 | $595,138,000 | $593,095,000 | $1,083,019,000 |
| Current Debt And Capital Lease Obligation | $8,685,000 | $7,574,000 | $502,656,000 | $10,375,000 |
| Net Debt | - | - | $331,845,000 | $358,488,000 |
| Current Debt | - | - | $493,877,000 | - |
| Other Current Borrowings | - | - | $493,877,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,507,023,000 | $1,330,950,000 | $1,890,054,000 | $1,771,918,000 |
| Total Non Current Liabilities Net Minority Interest | $747,992,000 | $723,962,000 | $713,030,000 | $1,183,034,000 |
| Other Non Current Liabilities | $150,816,000 | $128,824,000 | $119,935,000 | $100,015,000 |
| Current Liabilities | $759,031,000 | $606,988,000 | $1,177,024,000 | $588,884,000 |
| Other Current Liabilities | $31,007,000 | $13,056,000 | $33,853,000 | $28,526,000 |
| Payables And Accrued Expenses | $499,917,000 | $383,845,000 | $434,828,000 | $341,699,000 |
| Payables | $491,328,000 | $376,728,000 | $428,638,000 | $333,411,000 |
| Other Payable | $174,893,000 | $128,758,000 | $110,478,000 | $85,960,000 |
| Total Tax Payable | $3,667,000 | $12,567,000 | $2,651,000 | $16,213,000 |
| Income Tax Payable | $3,667,000 | $12,567,000 | $2,651,000 | $16,213,000 |
| Accounts Payable | $312,768,000 | $235,403,000 | $315,509,000 | $231,238,000 |
| Current Deferred Liabilities | - | $1,369,000 | $4,620,000 | $711,000 |
| Equity | ||||
| Common Stock Equity | $6,086,999,000 | $5,657,990,000 | $4,951,549,000 | $4,603,156,000 |
| Total Equity Gross Minority Interest | $6,086,999,000 | $5,657,990,000 | $4,951,549,000 | $4,603,156,000 |
| Stockholders Equity | $6,086,999,000 | $5,657,990,000 | $4,951,549,000 | $4,603,156,000 |
| Other Equity Interest | $-10,508,000 | $-11,227,000 | $-9,860,000 | $-8,859,000 |
| Gains Losses Not Affecting Retained Earnings | $-13,473,000 | $61,653,000 | $-28,788,000 | $-3,867,000 |
| Other Equity Adjustments | $-13,473,000 | $61,653,000 | $-28,788,000 | $-3,867,000 |
| Retained Earnings | $154,206,000 | $-194,695,000 | $-621,554,000 | $-789,199,000 |
| Other | ||||
| Ordinary Shares Number | $192,300,101 | $190,761,349 | $188,598,154 | $186,250,719 |
| Share Issued | $192,300,101 | $190,761,349 | $188,598,154 | $186,250,719 |
| Tangible Book Value | $5,676,963,000 | $5,206,513,000 | $4,460,649,000 | $4,068,388,000 |
| Invested Capital | $6,684,175,000 | $6,253,128,000 | $6,038,521,000 | $5,686,175,000 |
| Working Capital | $3,194,459,000 | $2,625,439,000 | $1,779,064,000 | $2,162,573,000 |
| Capital Lease Obligations | $8,685,000 | $7,574,000 | $8,779,000 | $10,375,000 |
| Total Capitalization | $6,684,175,000 | $6,253,128,000 | $5,544,644,000 | $5,686,175,000 |
| Additional Paid In Capital | $5,956,582,000 | $5,802,068,000 | $5,611,562,000 | $5,404,895,000 |
| Capital Stock | $192,000 | $191,000 | $189,000 | $186,000 |
| Common Stock | $192,000 | $191,000 | $189,000 | $186,000 |
| Current Capital Lease Obligation | $8,685,000 | $7,574,000 | $8,779,000 | $10,375,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $219,422,000 | $202,513,000 | $201,067,000 | $207,573,000 |
| Current Accrued Expenses | $8,589,000 | $7,117,000 | $6,190,000 | $8,288,000 |
| Investments And Advances | $492,242,000 | $521,238,000 | $611,135,000 | $333,835,000 |
| Available For Sale Securities | $492,242,000 | $521,238,000 | $611,135,000 | $333,835,000 |
| Goodwill | $196,199,000 | $196,199,000 | $196,199,000 | $196,199,000 |
| Net PPE | $952,508,000 | $1,043,041,000 | $1,066,133,000 | $1,073,366,000 |
| Accumulated Depreciation | $-1,074,305,000 | $-891,791,000 | $-867,089,000 | $-802,145,000 |
| Gross PPE | $2,026,813,000 | $1,934,832,000 | $1,933,222,000 | $1,875,511,000 |
| Leases | $44,035,000 | $44,368,000 | $58,230,000 | $59,532,000 |
| Construction In Progress | $134,911,000 | $90,271,000 | $100,013,000 | $143,384,000 |
| Other Properties | $574,576,000 | $542,856,000 | $538,677,000 | $475,663,000 |
| Machinery Furniture Equipment | $244,235,000 | $246,639,000 | $257,935,000 | $260,591,000 |
| Buildings And Improvements | $910,710,000 | $892,484,000 | $860,807,000 | $819,100,000 |
| Land And Improvements | $118,346,000 | $118,214,000 | $117,560,000 | $117,241,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $391,312,000 | $527,634,000 | $380,372,000 | $352,356,000 |
| Work In Process | $801,061,000 | $550,678,000 | $571,107,000 | $410,656,000 |
| Raw Materials | $106,510,000 | $154,341,000 | $155,704,000 | $131,071,000 |
| Other Short Term Investments | $248,930,000 | $194,864,000 | $318,683,000 | $567,006,000 |
| Current Deferred Revenue | - | $1,369,000 | $4,620,000 | $711,000 |
| Treasury Shares Number | - | - | $0 | - |
| Unrealized Gain Loss | - | - | - | $-12,093,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $717,019,000 | $475,423,000 | $51,648,000 | $44,362,000 |
| Operating Activities | ||||
| Operating Cash Flow | $827,994,000 | $572,841,000 | $159,259,000 | $175,902,000 |
| Cash Flow From Continuing Operating Activities | $827,994,000 | $572,841,000 | $159,259,000 | $175,902,000 |
| Operating Gains Losses | $4,459,000 | $-26,753,000 | $28,446,000 | $-122,287,000 |
| Investing Activities | ||||
| Capital Expenditure | $-110,975,000 | $-97,418,000 | $-107,611,000 | $-131,540,000 |
| Investing Cash Flow | $-414,242,000 | $136,491,000 | $-111,244,000 | $-20,029,000 |
| Cash Flow From Continuing Investing Activities | $-414,242,000 | $136,491,000 | $-111,244,000 | $-20,029,000 |
| Net Other Investing Changes | - | $11,141,000 | - | $103,325,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-42,394,000 | $-526,447,000 | $-18,727,000 | $-18,650,000 |
| Cash Flow From Continuing Financing Activities | $-42,394,000 | $-526,447,000 | $-18,727,000 | $-18,650,000 |
| Net Other Financing Charges | $-56,854,000 | $-80,737,000 | $-88,080,000 | $-87,983,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-494,987,000 | $0 | $0 |
| Interest Paid Supplemental Data | $7,245,000 | $10,361,000 | $10,303,000 | $10,281,000 |
| Income Tax Paid Supplemental Data | $96,205,000 | $57,269,000 | $73,312,000 | $54,372,000 |
| End Cash Position | $1,311,679,000 | $942,842,000 | $755,127,000 | $724,531,000 |
| Beginning Cash Position | $942,842,000 | $755,127,000 | $724,531,000 | $587,276,000 |
| Effect Of Exchange Rate Changes | $-2,521,000 | $4,830,000 | $1,308,000 | $32,000 |
| Changes In Cash | $371,358,000 | $182,885,000 | $29,288,000 | $137,223,000 |
| Proceeds From Stock Option Exercised | $14,460,000 | $49,277,000 | $69,353,000 | $69,333,000 |
| Net Issuance Payments Of Debt | $0 | $-494,987,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $-494,987,000 | $0 | $0 |
| Long Term Debt Payments | $0 | $-494,987,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-18,074,000 | $222,768,000 | $-3,633,000 | $8,186,000 |
| Sale Of Investment | $337,801,000 | $633,018,000 | $864,863,000 | $619,995,000 |
| Purchase Of Investment | $-355,875,000 | $-410,250,000 | $-868,496,000 | $-611,809,000 |
| Net Business Purchase And Sale | $-285,193,000 | $0 | $0 | - |
| Purchase Of Business | $-285,193,000 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-7,937,000 | $-11,994,000 | $-10,920,000 | $-10,581,000 |
| Purchase Of Intangibles | $-7,937,000 | $-11,994,000 | $-10,920,000 | $-10,581,000 |
| Net PPE Purchase And Sale | $-103,038,000 | $-85,424,000 | $-96,691,000 | $-120,959,000 |
| Purchase Of PPE | $-103,038,000 | $-85,424,000 | $-96,691,000 | $-120,959,000 |
| Change In Working Capital | $-293,660,000 | $-216,396,000 | $-336,539,000 | $-96,383,000 |
| Change In Other Current Liabilities | $14,869,000 | $14,761,000 | $23,585,000 | $6,933,000 |
| Change In Other Current Assets | $-29,682,000 | $-77,478,000 | $-81,484,000 | $-12,037,000 |
| Change In Payables And Accrued Expense | $66,136,000 | $-32,240,000 | $68,853,000 | $59,018,000 |
| Change In Payable | $66,136,000 | $-32,240,000 | $68,853,000 | $59,018,000 |
| Change In Account Payable | $66,136,000 | $-32,240,000 | $68,853,000 | $59,018,000 |
| Change In Inventory | $-116,929,000 | $-63,530,000 | $-157,058,000 | $-68,264,000 |
| Change In Receivables | $-228,054,000 | $-57,909,000 | $-190,435,000 | $-82,033,000 |
| Changes In Account Receivables | $-228,054,000 | $-57,909,000 | $-190,435,000 | $-82,033,000 |
| Other Non Cash Items | $219,171,000 | $23,494,000 | $3,823,000 | $3,778,000 |
| Stock Based Compensation | $181,409,000 | $201,571,000 | $207,099,000 | $196,308,000 |
| Asset Impairment Charge | $244,220,000 | $19,889,000 | $38,608,000 | $0 |
| Amortization Of Securities | $-4,801,000 | $-8,345,000 | $-9,228,000 | $3,043,000 |
| Deferred Tax | $48,738,000 | $56,096,000 | $-44,981,000 | $-52,087,000 |
| Deferred Income Tax | $48,738,000 | $56,096,000 | $-44,981,000 | $-52,087,000 |
| Depreciation Amortization Depletion | $79,557,000 | $96,426,000 | $104,386,000 | $101,969,000 |
| Depreciation And Amortization | $79,557,000 | $96,426,000 | $104,386,000 | $101,969,000 |
| Net Foreign Currency Exchange Gain Loss | $4,459,000 | $-16,753,000 | $28,446,000 | $-14,287,000 |
| Net Income From Continuing Operations | $348,901,000 | $426,859,000 | $167,645,000 | $141,561,000 |
| Issuance Of Debt | - | - | - | $0 |
| Common Stock Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Provisionand Write Offof Assets | - | - | - | $0 |
Fetched: 2026-06-15